Evidence map›Paper›PMID 38030222›Full record

ArticleLife science alliance2024

Correction: The coenzyme A precursor pantethine enhances antitumor immunity in sarcoma.

Richard Miallot, Virginie Millet, Anais Roger, Romain Fenouil, Catherine Tardivel, Jean-Charles Martin, Fabrice Tranchida, Laetitia Shintu, Paul Berchard, Juliane Sousa Lanza and 9 more

Open access · goldAbstract readPublished Erratum
In one paragraph

Article in Life science alliance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Richard MiallotINSERM, CNRS, Centre D'Immunologie de Marseille-Luminy, Aix-Marseille Université, Marseille, France richardmiallot@gmail.com.ORCID https://orcid.org/0009-0007-6795-6954
Virginie MilletINSERM, CNRS, Centre D'Immunologie de Marseille-Luminy, Aix-Marseille Université, Marseille, France.
Anais RogerINSERM, CNRS, Centre D'Immunologie de Marseille-Luminy, Aix-Marseille Université, Marseille, France.ORCID https://orcid.org/0000-0003-4872-3171
Romain FenouilINSERM, CNRS, Centre D'Immunologie de Marseille-Luminy, Aix-Marseille Université, Marseille, France.
Catherine TardivelINRAE, INSERM, C2VN, Aix Marseille Université, Marseille, France.
Jean-Charles MartinINRAE, INSERM, C2VN, Aix Marseille Université, Marseille, France.ORCID https://orcid.org/0000-0002-2870-0012
Fabrice TranchidaCNRS, Centrale Marseille, ISM2, Aix Marseille Université, Marseille, France.
Laetitia ShintuCNRS, Centrale Marseille, ISM2, Aix Marseille Université, Marseille, France.ORCID https://orcid.org/0000-0003-2730-121X
Paul BerchardINSERM 1052, CNRS 5286, Cancer Research Center of Lyon (CRCL), Childhood Cancers and Cell Death Laboratory, Lyon, France.
Juliane Sousa LanzaINSERM, CNRS, Centre D'Immunologie de Marseille-Luminy, Aix-Marseille Université, Marseille, France.
Bernard MalissenINSERM, CNRS, Centre D'Immunologie de Marseille-Luminy, Aix-Marseille Université, Marseille, France.ORCID https://orcid.org/0000-0003-1340-9342
Sandrine HenriINSERM, CNRS, Centre D'Immunologie de Marseille-Luminy, Aix-Marseille Université, Marseille, France.ORCID https://orcid.org/0000-0002-8980-9193
Sophie UgoliniINSERM, CNRS, Centre D'Immunologie de Marseille-Luminy, Aix-Marseille Université, Marseille, France.ORCID https://orcid.org/0000-0003-4041-0103
Aurélie DutourINSERM 1052, CNRS 5286, Cancer Research Center of Lyon (CRCL), Childhood Cancers and Cell Death Laboratory, Lyon, France.
Pascal FinettiINSERM, CNRS, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes (IPC), Laboratory of Predictive Oncology, Aix-Marseille Université, Marseille, France.ORCID https://orcid.org/0000-0002-2674-3123
François BertucciINSERM, CNRS, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes (IPC), Laboratory of Predictive Oncology, Aix-Marseille Université, Marseille, France.
Jean-Yves BlayINSERM 1052, CNRS 5286, Cancer Research Center of Lyon (CRCL), Childhood Cancers and Cell Death Laboratory, Lyon, France.ORCID https://orcid.org/0000-0001-7190-120X
Franck GallandINSERM, CNRS, Centre D'Immunologie de Marseille-Luminy, Aix-Marseille Université, Marseille, France.ORCID https://orcid.org/0000-0003-4381-1308
Philippe NaquetINSERM, CNRS, Centre D'Immunologie de Marseille-Luminy, Aix-Marseille Université, Marseille, France naquet@ciml.univ-mrs.fr.ORCID https://orcid.org/0000-0002-2907-7808
Inserm · FRCentre National de la Recherche Scientifique · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38030222
PMCPMC10690990
OpenAlexW4389131681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.